Arcellx, INC Form 4 insider transactions

Arcellx Chief Medical Officer Christopher Heery sold 12,396 shares of common stock for approximately $80.12 per share pursuant to a pre-arranged trading plan.

Arcellx Chief Medical Officer Christopher Heery sold 3,643 shares of common stock in September 2025 under a pre-arranged 10b5-1 trading plan.

Arcellx, Inc.'s President, CEO, and Chairman, Rami Elghandour, forfeited 546,938 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Arcellx Director Ali Behbahani increased his beneficial ownership of company common stock through a pro rata distribution from NEA Partners 15, L.P.

Arcellx, Inc. Director Kavita Patel completed a pre-scheduled transaction, exercising stock options to acquire 1,500 shares and immediately selling them for a significant profit under a Rule 10b5-1 trading plan.

Arcellx, Inc. Director and 10% Owner Ali Behbahani was granted 9,174 stock options with an exercise price of $63.68, vesting by May 29, 2026, or the next annual meeting.

Arcellx, Inc. Director Andrew H. Galligan was granted 1,784 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Arcellx, Inc. Director Kavita Patel was granted 9,174 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Arcellx, Inc. director Kristin Myers was granted 1,784 stock options with an exercise price of $63.68, aligning her interests with shareholders.

Arcellx, Inc. Director Olivia C. Ware was granted 9,174 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Arcellx, Inc. Director Jill Carroll was granted 9,174 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Arcellx, Inc. Director David Charles Lubner was granted 9,174 stock options with an exercise price of $63.68, vesting by May 29, 2026, or the next annual meeting.

Arcellx, Inc.'s Chief Financial Officer, Michelle Gilson, reported the vesting of restricted stock units and subsequent sales of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. on May 20, 2025, according to a Form 4 filing.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged 10b5-1 trading plan.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged 10b5-1 trading plan.

Director Kristin Myers acquired stock options for 16,829 shares of Arcellx, Inc. on March 18, 2025.

Director Andrew H. Galligan acquired stock options for 16,829 shares of Arcellx, Inc. (ACLX) on March 18, 2025.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged 10b5-1 trading plan.

Arcellx CEO Rami Elghandour acquired shares of common stock on February 27, 2025, following the achievement of performance criteria related to restricted stock awards.

Arcellx CEO Rami Elghandour sold shares of common stock on February 26, 2025, to cover tax obligations related to the vesting of restricted stock units.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged 10b5-1 trading plan.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports selling shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports exercising stock options and acquiring 22,556 shares of common stock on February 7, 2025.

Arcellx CEO Rami Elghandour reports the disposition of 70,211 shares of common stock and the vesting of 70,211 restricted stock units on February 7, 2025.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Arcellx director, Kavita Patel, exercised stock options and sold shares on January 14, 2025, under a pre-arranged 10b5-1 trading plan.

Arcellx's Chief Medical Officer, Christopher Heery, sold a portion of his shares to cover tax obligations following the vesting of restricted stock units.

Arcellx's Chief Financial Officer, Michelle Gilson, executed multiple sales of company stock under a pre-arranged 10b5-1 trading plan, along with sales to cover tax obligations related to vesting restricted stock units.

Arcellx CEO Rami Elghandour sold shares to cover tax obligations following the vesting of restricted stock units.